Peptide therapy may cause mild side effects such as local swelling, discomfort, fatigue or nausea
DPP-4 Inhibitors As mentioned above, DPP-4 inhibitors are now an established and successful class of oral anti-hyperglycaemic agents, and are firmly embedded in guidelines for treating T2DM patients without atherosclerotic cardiovascular (CV) disease (116, 117)
This allows patients to receive high-quality, personalized medication shipped directly to their doors after a thorough clinical consultation
Eli Lilly is targeting an FDA submission in late 2026, with an MHRA submission expected to follow within a few months
For many people, especially first-time users, that simplicity makes Mounjaro the easiest tirzepatide option to use